Li Jianshuang, Lu Di, Liu Huadie, Williams Bart O, Overbeek Paul A, Lee Brendan, Zheng Ling, Yang Tao
Hubei Key Laboratory of Cell Homeostasis, Department of Cell Biology, College of Life Sciences, Wuhan University, Wuhan, Hubei 430072, P.R. China.
Program for Skeletal Disease and Tumor Metastasis, Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, MI 49503, USA.
Hum Mol Genet. 2017 Aug 1;26(15):2949-2960. doi: 10.1093/hmg/ddx183.
Ciliopathies form a group of inherited disorders sharing several clinical manifestations because of abnormal cilia formation or function, and few treatments have been successful against these disorders. Here, we report a mouse model with mutated Sclt1 gene, which encodes a centriole distal appendage protein important for ciliogenesis. Sodium channel and clathrin linker 1 (SCLT1) mutations were associated with the oral-facial-digital syndrome (OFD), an autosomal recessive ciliopathy. The Sclt1-/- mice exhibit typical ciliopathy phenotypes, including cystic kidney, cleft palate and polydactyly. Sclt1-loss decreases the number of cilia in kidney; increases proliferation and apoptosis of renal tubule epithelial cells; elevates protein kinase A, extracellular signal-regulated kinases, SMAD and signal transducer and activator of transcription 3 (STAT3) pathways; and enhances pro-inflammation and pro-fibrosis pathways with disease progression. Embryonic kidney cyst formation of Sclt1-/- mice was effectively reduced by an anti-STAT3 treatment using pyrimethamine. Overall, we reported a new mouse model for the OFD; and our data suggest that STAT3 inhibition may be a promising treatment for SCLT1-associated cystic kidney.
纤毛病是一组遗传性疾病,由于纤毛形成或功能异常而具有多种临床表现,针对这些疾病的成功治疗方法很少。在此,我们报告了一种Sclt1基因突变的小鼠模型,该基因编码一种对纤毛发生很重要的中心粒远端附属蛋白。钠通道和网格蛋白连接蛋白1(SCLT1)突变与常染色体隐性纤毛病——口面指综合征(OFD)相关。Sclt1基因敲除小鼠表现出典型的纤毛病表型,包括多囊肾、腭裂和多指畸形。Sclt1缺失会减少肾脏中的纤毛数量;增加肾小管上皮细胞的增殖和凋亡;提高蛋白激酶A、细胞外信号调节激酶、SMAD和信号转导及转录激活因子3(STAT3)通路的活性;并随着疾病进展增强促炎和促纤维化通路。使用乙胺嘧啶进行抗STAT3治疗可有效减少Sclt1基因敲除小鼠胚胎肾囊肿的形成。总体而言,我们报告了一种新的OFD小鼠模型;我们的数据表明,抑制STAT3可能是治疗SCLT1相关多囊肾的一种有前景的方法。